Hypha's Q1 2023 newsletter No images? Click here Hypha DiscoveryWhat's New Q1 2023![]() Focus Feature - Recombinant Metabolising EnzymesRecombinant enzymes are a valuable tool for making metabolites. If you're a PolyCYPs user, then you'll be familiar with the screening kits we have available. We have over 100 isoforms in our PolyCYPs platform which are available for testing at Hypha. The Recombinant Technologies team have been busy exemplifying additional capability such as one new PolyCYP which catalyses a hydroxylation reaction to a pirfenidone metabolite at 60% conversion, matching to the human CYP1A2 product. PolyCYP 609 is quite a selective CYP compared to some of the more promiscuous isoforms in the kit, but has been shown to also metabolise 7-ethoxycoumarin and celecoxib. ![]() Phase II capability of some new recombinant microbial UGTs adds to the tools available for making glucuronides and glycosides. We undertake projects for clients using a variety of recombinant enzymes, in addition to the other biotransformation tools and chemical synthesis capabilities we have in house. If you'd like to try out our PolyCYPs kits, or are interested in discussing a metabolite project, just reply to this email or contact us through our website. We love client feedback From a US client about some structure elucidation work we did using cryoprobe NMR, using only 10s of micrograms of material: Read our latest blogOur “Metabolite Tales” blogs are science-focused articles on interesting aspects around metabolism and medicinal chemistry in drug discovery and development. Metabolism of 2022 FDA approved small molecule drugs – Part 1In Part 1 of this blog on metabolism of small molecules approved by the FDA in 2022, we look at the trends, and whether CYP3A4 still rules.Other blog articlesHave a look at the blog articles we published last year here. ![]() There’s moreIf you're interested in keeping up with what's happening at Hypha Discovery, follow us on LinkedIn for regular updates. |